 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...2425262728293031323334...7475» |
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Effect of subretinal fluid (SRF) resolution on visual acuity in patients with neovascular age-related macular degeneration (nAMD) () - May 13, 2021 - Abstract #ARVO2021ARVO_1809;
P3
Loss of ≥4 ETDRS letters at the time of SRF resolution may portend worse long- term visual outcomes. Treating eyes to SRF resolution may be deleterious in some.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Impact of Duration of Exposure to Residual Intraretinal Fluid on Visual Function Outcomes in Neovascular Age-Related Macular Degeneration () - May 13, 2021 - Abstract #ARVO2021ARVO_1806;
Treating eyes to SRF resolution may be deleterious in some. In this analysis of patients treated with intravitreal aflibercept and ranibizumab in VIEW 1 and 2, longer duration of exposure to residual IRF was associated with lower visual acuity gain and worse vision-related quality of life outcomes.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) () - May 13, 2021 - Abstract #ARVO2021ARVO_1805;
Among eyes with baseline SRF, mean VA in eyes with persistent SRF through 12 wks, 1 yr, or 2 yrs of PRN treatment was similar to eyes in which SRF resolved. Persistent SRF >200 µm thick at the foveal center was rare.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] COVID-19 pandemic lockdown international impact on nAMD, DME and RVO intravitreal therapy outcomes: Fight Retinal Blindness International registry () - May 13, 2021 - Abstract #ARVO2021ARVO_1781;
This study provides accurate estimates of the impact of COVID-19 pandemic lockdown on the visual outcomes of an international cohort of eyes treated with intravitreal therapy. The data reported in this study may serve clinicians to prepare strategies to mitigate vision loss in future scenarios of the COVID-19 pandemic evolution.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Long-term efficacy and treatment burden of treat-and-extend versus fixed or PRN regimens for nAMD: a systematic review and meta-analysis. () - May 13, 2021 - Abstract #ARVO2021ARVO_1603;
Patients on a PRN regimen receive fewer injections than those on T&E dosing, but with less favourable visual outcomes. Additional studies are required for more robust meta-analysis of anti-VEGF injection frequency at 1 year and beyond.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Investigating the Arden hypothesis: a one-year trial investigating the prevention of dark adaptation as complementary therapy for diabetic macular edema () - May 13, 2021 - Abstract #ARVO2021ARVO_1207;
Use of a lighted sleep mask poses a challenge for a majority of patients treated for CSME with anti- VEGF injections. There is insufficient evidence to evaluate the effectiveness of light-at-night delivered by this means as a complementary therapy for diabetic retinopathy.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Ocular Inflammatory and Retinal Vascular Occlusive Adverse Events of Intravitreal anti-VEGF Injections: A Systematic Review and Network Meta-analysis () - May 13, 2021 - Abstract #ARVO2021ARVO_1120;
The reported rates of OAE are generally low across the different anti-VEGFs but appear higher for newer agents brolucizumab and especially, abicipar. Further trials are needed to adequately assess their safety profile.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Anti-VEGF drugs clearly decrease phagocytic ability of retinal microglia. () - May 13, 2021 - Abstract #ARVO2021ARVO_1116;
In contrast, their ability to phagocytose is reduced dramatically. It may be speculated that reduced microglial phagocytosis allows enhanced accumulation of cellular debris, which in turn may promote progression of dry AMD.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Toward a Non-Invasive Solution of Wet AMD: Sunitinib, Pazopanib, and Axitinib Eyedrops versus Intraocular Injection of Aflibercept () - May 13, 2021 - Abstract #ARVO2021ARVO_1115;
Corresponding ocular pharmacokinetic study and tissue distribution analysis of TKI dispersion support the straightforward way of drug delivery through the cornea to the retina. Further efforts to develop the TKI eyedrops for patient-friendly wet AMD treatments are under way.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Levels of systemic VEGF-A and ranibizumab in the infant of a nursing mother receiving intravitreal ranibizumab therapy followed by a ‘pump and dump’ strategy () - May 13, 2021 - Abstract #ARVO2021ARVO_1114;
Ranibizumab was not detected in the infant of a nursing mother who received intravitreal ranibizumab injection followed by a 3-day ‘pump and dump’ strategy and systemic VEGF-A levels did not seem to be affected. This suggests that a 3-day ‘pump and dump’ strategy could possibly be a safe option for nursing mothers who require intravitreal ranibizumab therapy but want to continue breastfeeding.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Treatment switch from aflibercept to ranibizumab pre-filled syringe in Canadian DME patients in a real-world setting: The PRECISE study () - May 13, 2021 - Abstract #ARVO2021ARVO_1108;
Real-world evidence from the PRECISE study provides useful information that the key reason for treatment switch was lack of response to AFL treatment, primarily due to presence of fluid in the macula. Results from our study will further our current understanding and enhance routine clinical care of these patients.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Efficacy of the Treat-and-Extend Regimen in the Management of Neovascular Age-Related Macular Degeneration: 7-Year Results of the RENO Study () - May 13, 2021 - Abstract #ARVO2021ARVO_1105;
The Treat-and-Extend regimen was effective in maintaining visual acuity in patients with nAMD treated with ranibizumab, aflibercept, bevacizumab, or brolucizumab for up to 7 years of treatment in patients who received a minimum of 6 injections in the first year and a minimum of 3 injections in follow-up years 2 through 7. To reduce overall treatment burden, the Treat-and-Extend regimen is an effective treatment option for patients.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Intravitreal injection patterns between retina providers in treating Wet Age-Related Macular Degeneration in a single hospital-based setting () - May 13, 2021 - Abstract #ARVO2021ARVO_1103;
Qualified subjects included a diagnosis of wet AMD (18-100 years) who received Bevacizumab, Ranibizumab, or Aflibercept eye injections. Because significantly different intravitreal injection patterns resulted in similar visual outcomes, adopting a “best practice“ recommendation may decrease treatment and financial burden in wet AMD patients.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Pharmacokinetic profile of the Port Delivery System with ranibizumab (PDS) in the phase 3 Archway trial () - May 13, 2021 - Abstract #ARVO2021ARVO_1089;
P3
Ranibizumab concentrations with PDS 100 mg/mL Q24W are within the range experienced with monthly intravitreal ranibizumab 0.5 mg injections. Aqueous humor PK were consistent with serum PK.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Prediction of ranibizumab injection frequency in patients with macular edema due to retinal vein occlusion during as-needed dosing period of BRAVO and CRUISE Phase 3 trials () - May 13, 2021 - Abstract #ARVO2021ARVO_1082;
The average of BCVA values at BL, M1, M2 and M3 was associated with the greatest predictive signal of future injection need. Imaging features increased predictive performance of the model.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Changes in retinal sensitivity, thickness, and perfusion density following treatment for branch retinal vein occlusion (BRVO) () - May 13, 2021 - Abstract #ARVO2021ARVO_938;
Twelve months after initiation of therapy, RS improved in the IVR monotherapy arm but not in eyes requiring combination therapy. These findings may be of value in assessing prognosis in eyes with BRVO.
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] The role of Optical Coherence Tomography Angiography in detecting and monitoring inflammatory choroidal neovascular membranes () - May 13, 2021 - Abstract #ARVO2021ARVO_712;
Treatment for i-CNVM included intravitreal bevacizumab (n=1), intravitreal ranibizumab (n=2), intravitreal aflibercept (n=8), subtenon triamcinolone acetonide (n=2) and intravitreal dexamethasone implant (n=2)... Our results show that OCT-A is an effective modality for detecting i-CNVM and that visible regression of the CNVM is apparent in the majority of cases following treatment.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Trends in Endophthalmitis Associated with Intravitreal Injection of Anti-VEGF Agents from 2018-2020 at a Tertiary Referral Center () - May 13, 2021 - Abstract #ARVO2021ARVO_677;
Poor VA outcomes continue being associated with Streptococcus species. Nutritionally variant streptococci may be a rare cause of endophthalmitis after IV anti-VEGF injection.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Systemic immunosuppression and risk of endophthalmitis after intravitreal anti-vascular endothelial growth factor injections () - May 13, 2021 - Abstract #ARVO2021ARVO_675;
However, final visual outcomes following post-injection endophthalmitis treatment is similar regardless of systemic immunosuppression status. Additional studies are indicated to further elucidate the role, if any, of immunosuppressive therapy in the management of PIE.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Predictors of visual recovery after post-injection endophthalmitis () - May 13, 2021 - Abstract #ARVO2021ARVO_663;
Although frequently done at recurrent intervals, cumulative injections are not associated with worse visual outcomes following endophthalmitis. Factors that were associated with poor visual prognosis included the culture positivity and the need for a vitrectomy in the post infection period.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Subretinal Hyperreflective Material on Structural OCT in nAMD () - May 13, 2021 - Abstract #ARVO2021ARVO_654;
These were nAMD consecutive cases and we followed them for up to five years to investigate the incidence of subretinal hyperreflective material during nAMD treatment with ranibizumab and bevacizumab. The appearance of subretinal hyperreflective material on OCT during treatment with anti-vegf for nAMD is possible and suggests worse visual prognosis when compared to patients with no hyperreflective material
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Galectin-3 requires VEGF to activate VEGF receptor 2 in retinal endothelial cells () - May 13, 2021 - Abstract #ARVO2021ARVO_355;
VEGF neutralization was attained with ranibizumab (10 μg/ml)... Any VEGF is necessary for Gal3 induced kinase activation and HREC migration but endogenous Gal3 is not sufficient for VEGF/VEGFR2 signal transduction.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Impact of baseline vitreomacular interface status on the treatment choice between aflibercept, bevacizumab or ranibizumab for diabetic macular edema () - May 13, 2021 - Abstract #ARVO2021ARVO_115;
This study adds evidence that the VMI status impacts functional outcomes in patients with DME treated with anti-VEGF agents. Patients with total or partial VMA at baseline may derive greater improvements in visual acuity after anti-VEGF treatment compared with those with total PVD.
- faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials () - May 13, 2021 - Abstract #ARVO2021ARVO_112;
P3
In BOULEVARD, faricimab Q4W demonstrated superior vision gains and greater improvements in diabetic retinopathy severity at week 24, and showed potential for extended durability in a 16-week off-treatment observation period, when compared with ranibizumab Q4W. YOSEMITE and RHINE evaluate the efficacy, durability, and safety of faricimab Q8W or per PTI, a protocol-driven regimen based on treat-and-extend, in patients with DME.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Comparison of real-life treatment of naïve patients with ranibizumab over 24 months for neovascular AMD, diabetic macular edema, retinal vein occlusion and myopic CNV – results of the current interim analysis of the PACIFIC study () - May 13, 2021 - Abstract #ARVO2021ARVO_28;
The PACIFIC study provides real-life data on therapy with anti-VEGF ranibizumab and on routine health care structural use. The value of observational insights from routine clinical practice may lead to a better understanding of status quo and challenges in patient health care under real life settings.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Ten year outcome of neovascular age-related macular degeneration: association of functional and anatomical treatment outcomes with major risk allele for the disease () - May 13, 2021 - Abstract #ARVO2021ARVO_13;
nvAMD patients under anti-VEGF therapy for over 10 years encounter a substantial mean vision loss that is influenced by the presence of IRF at baseline and by atrophy rather than re-thickening of the macula at follow- up. Major complement risk alleles for AMD are associated with a lesser reduction in baseline macula thickness in the long-term.
- || Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Clinical, Journal: Ranibizumab Alters Levels of Intraocular Soluble Cytokine Receptors in Patients with Diabetic Macular Edema. (Pubmed Central) - May 13, 2021
Ranibizumab treatment had strong effects on regulating levels of soluble receptors closely linked to IL-1 and IL-6 signaling pathways. Therefore, a complete understanding of the actions of ranibizumab will further the development of additional therapies to support treatment of diabetic macular edema.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Intravitreal ranibizumab reduced ocular blood flow and aqueous cytokine levels and improved retinal morphology in patients with diabetic macular edema. (Pubmed Central) - May 13, 2021
We conclude that IRI reduces both retinal and choroidal blood flow in treatment-naïve DME. Reduction of retinal blood flow correlated with regression of morphological pathology, which is regulated by the initial aqueous levels of some cytokines.
- || CMAB818 (ranibizumab biosimilar) / 3SBio
New P1 trial: Phase I Study to Compare CMAB818 Injection and Lucentis (clinicaltrials.gov) - May 12, 2021
P1, N=24, Not yet recruiting, Sponsor: Shanghai Biomabs Pharmaceutical Co., Ltd.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, HEOR: Cost-Minimization Analysis of Ranibizumab Versus Aflibercept for Treating Saudi Patients With Visual Impairment Owing to Age-Related Macular Degeneration or Diabetic Macular Edema. (Pubmed Central) - May 12, 2021
Reduction of retinal blood flow correlated with regression of morphological pathology, which is regulated by the initial aqueous levels of some cytokines. From the third-party payer perspective, aflibercept is a cost-containment option that provides substantial savings over ranibizumab for treating Saudi patients with AMD or DME.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Reflux, Intraocular Pressure Variation and Pain Following Intravitreal Ranibizumab Injections Using 30-Gauge or 32-Gauge Needles for Patients With Retinal Pathologies: A Randomized Clinical Trial. (Pubmed Central) - May 11, 2021
IV injection given by 30-gauge needle compared to 32-gauge needle resulted in greater patient-perceived pain and more reflux of injected material from the injection site. An increase in IOP was not associated with the gauge of the needle used for IV injection.
- | Lucentis (ranibizumab) / Roche, Novartis
New P1 trial, Surgery: Effects of Ranibizumab in Primary Pterygium Surgery (clinicaltrials.gov) - May 9, 2021
P1, N=52, Completed, Sponsor: Universiti Sains Malaysia
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. (Pubmed Central) - May 9, 2021
Avoiding temperature fluctuation, mechanical shock, agitation during transport and handling of syringes/drugs, and the use of SO-free syringes may help minimize intraocular inflammation. While a definitive mechanism has not yet been established, current knowledge of the clinical presentation and vitreous histopathology of brolucizumab-retinal vasculitis favors an auto-immune type IV hypersensitivity reaction.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Visual Outcomes after Anti-VEGF Therapy for Exudative Age-Related Macular Degeneration in a Real-Life Setting. (Pubmed Central) - May 7, 2021
While a definitive mechanism has not yet been established, current knowledge of the clinical presentation and vitreous histopathology of brolucizumab-retinal vasculitis favors an auto-immune type IV hypersensitivity reaction. Anti-VEGF therapy carried out in a real-life setting shows good VA outcomes with a favorable safety profile.
- | Lucentis (ranibizumab) / Roche, Novartis
Preclinical, Journal: The Role of Intravitreal Anti-VEGF Agents in Rabbit Eye Model of Open-Globe Injury. (Pubmed Central) - May 7, 2021
Both Ranibizumab and Conbercept inhibited epiretinal scar formation at the wound site, with Conbercept showing the greatest effect (maximal length of scar (L), L = 503 ± 82.44 μm, L = 355 ± 43.66 μm, and L = 250.33 ± 36.02 μm). Anti-VEGF treatments after OGI significantly attenuated the upregulation of growth factors and cytokines in the vitreous and prevented intravitreal proliferation and epiretinal scar formation and thus may protect against the development of posttraumatic complications such as proliferative vitreoretinopathy (PVR).
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Clinical Features, Prognosis, and Long-Term Response to Ranibizumab of Macular CNVs in Pattern Dystrophies Spectrum: A Pilot Study. (Pubmed Central) - May 7, 2021
Early and long-term morphofunctional features of CNVs in PD and in AMD are overlapping. CNVs in PD have poorer long-term response to ranibizumab and higher choroidal thickness suggesting different pathogenetic and evolutionary mechanisms.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Fluorescein angiographic characteristic in predominantly classic and occult types of neovascular age-related macular degeneration treated with ranibizumab. (Pubmed Central) - May 6, 2021
The OCC-n-AMD patients had better baseline and follow-up VA and CMT means than the PDC-n-AMD patients. However, the PDC-n-AMD patients are expected to benefit more than the OCC-n-AMD patients in terms of VA gains.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: GENETICS OF LARGE PIGMENT EPITHELIAL DETACHMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. (Pubmed Central) - May 5, 2021
P3
However, the PDC-n-AMD patients are expected to benefit more than the OCC-n-AMD patients in terms of VA gains. In our series, the genotype GG of C3 rs2230199 was more significantly associated with the phenotype of large vascularized pigment epithelial detachment poorly responding to anti-vascular endothelial growth factor therapy than in global AMD series.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Clinical data, Journal: PRAGMATISM OF RANDOMIZED CLINICAL TRIALS ON RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA: Impact on Clinical Outcomes. (Pubmed Central) - May 5, 2021
Randomized clinical trials evaluating ranibizumab for diabetic macular edema were more pragmatic than explanatory. "Ineligible" patients still benefited from ranibizumab therapy.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Non-invasive molecular tracking method that measures ocular drug distribution in non-human primates. (Pubmed Central) - May 5, 2021
We further investigate a long acting anti-VEGF antibody, which remains as an agglomerate with some material leaking out until the end of the study at Day 35. Overall, we were able to visualize and measure differences in the in vivo behavior between short and long-acting antibodies, demonstrating the power of the technology for ocular pharmacokinetics.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Clinical data, Journal, Real-world evidence: Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years' Real-World Clinical Outcomes. (Pubmed Central) - May 4, 2021
We report VA improvement from all three different treatment regimens with both Aflibercept-Fixed and Ranibizumab-T&E regimens achieving the same higher final VA. Aflibercept-Fixed dosing may have more favorable efficacy with the highest VA gain and comparatively lower dosing frequency whereas Ranibizumab-T&E may be more efficient than Ranibizumab-PRN regimen, according to our study.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Efficacy of Antiangiogenic Drugs in the Treatment of Diabetic Macular Edema: A Bayesian Network Analysis. (Pubmed Central) - May 4, 2021
This conclusion may provide clinical evidence to guide treatment decisions. However, more high-quality randomized controlled trials will be necessary to further confirm this.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. (Pubmed Central) - May 1, 2021
P1/2
However, more high-quality randomized controlled trials will be necessary to further confirm this. The improvements achieved after 2 years of treat-and-extend ranibizumab for DME were maintained in the third year with a mean of 3 intravitreal injections.
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Generation of a Lentiviral Based Gene Therapy Vector for the Treatment of Neovascular Age-Related Macular Degeneration (nAMD) () - Apr 30, 2021 - Abstract #ASGCT2021ASGCT_540;
P1
Vascular endothelial growth factor (VEGF) is a pro-angiogenic factor that is known to have a key role in the development of nAMD and anti-VEGF treatments such as Aflibercept, Ranibizumab and Bevacizumab are the current standard of care for this disease...As such, we have developed an EIAV (OXB-203E) and HIV (OXB-203H) lentiviral vector encoding Aflibercept for the treatment of nAMD.Clinical data from RetinoStat®/OXB-201, a predecessor EIAV (equine infectious anaemia virus) gene therapy vector for the treatment of nAMD, expressing endostatin and angiostatin, demonstrated that following a single subretinal injection of this vector in patients, there was stable, long term expression of the transgenes in the aqueous humour out to 6 years, providing proof-of-principle for this type of single-injection gene therapy approach (NCT01301443 (Phase I GEM study) and NCT01678872 (follow-up study)).OXB-203 is the successor to our nAMD programme...In a preclinical study using a rat choroidal neovascularization (CNV) model for nAMD, a single subretinal administration of OXB-203E demonstrated expression of Aflibercept in the vitreous humour and reduction of laser-induced CNV lesion areas comparable to a bolus of recombinant Aflibercept delivered intravitreally. An in vivo head to head comparative study of OXB-203 and an AAV8-Aflibercept vector showed that Aflibercept derived from OXB-203 lentiviral vectors was expressed at significantly higher levels than from the AAV8-Aflibercept in the rat vitreous humour, retina and choroid (with retinal pigment epithelium (RPE)), four weeks following a single subretinal delivery of the viral vectors.These studies demonstrate the comparable efficacy of the OXB-203 lentiviral vector to that of recombinant Aflibercept and the superiority of OXB-203 in terms of the level of Aflibercept expression over an AAV8-based vector, thereby supporting the therapeutic potential of OXB-203 for the management of nAMD.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Evaluation of Port Delivery System with ranibizumab for the treatment of neovascular age-related macular degeneration. (Pubmed Central) - Apr 30, 2021
The Port Delivery System with ranibizumab offers a long-term solution that involves implantation of a device into the pars plana and provides continuous release of anti-VEGF medication into the vitreous, thus requiring fewer office visits. The Port Delivery System has demonstrated comparable visual and anatomic outcomes to monthly injections and shows promise in alleviating the patient burden in the treatment of neovascular age-related macular degeneration, making possible better long-term real-world visual outcomes.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Re: Bontzos et al.: Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study (Ophthalmol Retina. 2020;4:1138-1145). (Pubmed Central) - Apr 30, 2021
The Port Delivery System has demonstrated comparable visual and anatomic outcomes to monthly injections and shows promise in alleviating the patient burden in the treatment of neovascular age-related macular degeneration, making possible better long-term real-world visual outcomes. No abstract available
- | Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: VITCLEAR: A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy. (clinicaltrials.gov) - Apr 30, 2021
P=N/A, N=59, Completed, Sponsor: King's College Hospital NHS Trust
No abstract available Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: COVERT: Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab (clinicaltrials.gov) - Apr 28, 2021
P4, N=168, Recruiting, Sponsor: Unity Health Toronto
Active, not recruiting --> Completed Trial completion date: Feb 2020 --> Feb 2024 | Trial primary completion date: Feb 2020 --> Feb 2024
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Anti-VEGF therapy of wet age-related macular degeneration: analysis of patients lost to follow-up (Pubmed Central) - Apr 28, 2021
Trial completion date: Feb 2020 --> Feb 2024 | Trial primary completion date: Feb 2020 --> Feb 2024 In accordance with identified reasons for LTFU, we determined the directions for increasing the effectiveness of wAMD treatment: early diagnosis and start of treatment; using the most effective drugs and therapeutic regimens; increasing the availability of anti-VEGF therapy.
- || LKA651 / Novartis, MorphoSys
Trial completion date, Trial primary completion date: Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Apr 28, 2021
P2, N=90, Recruiting, Sponsor: Novartis Pharmaceuticals
In accordance with identified reasons for LTFU, we determined the directions for increasing the effectiveness of wAMD treatment: early diagnosis and start of treatment; using the most effective drugs and therapeutic regimens; increasing the availability of anti-VEGF therapy. Trial completion date: Nov 2021 --> Dec 2022 | Trial primary completion date: Nov 2021 --> Dec 2022